|
1
|
Karim-Kos HE, de Vries E, Soerjomataram I,
Lemmens V, Siesling S and Coebergh JW: Recent trends of cancer in
Europe: A combined approach of incidence, survival and mortality
for 17 cancer sites since the 1990s. Eur J Cancer. 44:1345–1389.
2008. View Article : Google Scholar
|
|
2
|
International Agency for Research on
Cancer WHO Pancreas: Source: Globocan 2020. Available from:
http://gcoiarcfr/today/data/factsheets/cancers/13-Pancreas-fact-sheetpdf.
2020
|
|
3
|
American Cancer Society: Cancer Facts and
Figures. 2019.
|
|
4
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe Estimates
for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar
|
|
6
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carrato A, Falcone A, Ducreux M, Valle JW,
Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C and
Parthenaki I: A systematic review of the burden of pancreatic
cancer in europe: Real-world impact on survival, quality of life
and costs. J Gastrointest Cancer. 46:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aune D, Greenwood DC, Chan DS, Vieira R,
Vieira AR, Navarro Rosenblatt DA, Cade JE, Burley VJ and Norat T:
Body mass index, abdominal fatness and pancreatic cancer risk: A
systematic review and non-linear dose-response meta-analysis of
prospective studies. Ann Oncol. 23:843–852. 2012. View Article : Google Scholar
|
|
9
|
Nöthlings U, Wilkens LR, Murphy SP, Hankin
JH, Henderson BE and Kolonel LN: Body mass index and physical
activity as risk factors for pancreatic cancer: The multiethnic
cohort study. Cancer Causes Control. 18:165–175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pratapwar M, Stenzel AE, Joseph JM,
Fountzilas C, Etter JL, Mongiovi JM, Cannioto R and Moysich KB:
Physical inactivity and pancreatic cancer mortality. J Gastrointest
Cancer. 51:1088–1093. 2020. View Article : Google Scholar
|
|
11
|
Bosetti C, Lucenteforte E, Silverman DT,
Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, et
al: Cigarette smoking and pancreatic cancer: An analysis from the
international pancreatic cancer case-control consortium (Panc4).
Ann Oncol. 23:1880–1888. 2012. View Article : Google Scholar :
|
|
12
|
Iodice S, Gandini S, Maisonneuve P and
Lowenfels AB: Tobacco and the risk of pancreatic cancer: A review
and meta-analysis. Langenbecks Arch Surg. 393:535–545. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duell EJ, Lucenteforte E, Olson SH, Bracci
PM, Li D, Risch HA, Silverman DT, Ji BT, Gallinger S, Holly EA, et
al: Pancreatitis and pancreatic cancer risk: A pooled analysis in
the international pancreatic cancer case-control consortium
(PanC4). Ann Oncol. 23:2964–2970. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rebours V, Boutron-Ruault MC, Schnee M,
Férec C, Maire F, Hammel P, Ruszniewski P and Lévy P: Risk of
pancreatic adenocarcinoma in patients with hereditary pancreatitis:
A national exhaustive series. Am J Gastroenterol. 103:111–119.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang
W, Zhang H and Li Z: Diabetes mellitus and risk of pancreatic
cancer: A meta-analysis of cohort studies. Eur J Cancer.
47:1928–1937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McWilliams RR, Maisonneuve P, Bamlet WR,
Petersen GM, Li D, Risch HA, Yu H, Fontham ET, Luckett B, Bosetti
C, et al: Risk factors for early-onset and very-early-onset
pancreatic adenocarcinoma: A pancreatic cancer case-control
consortium (PanC4) analysis. Pancreas. 45:311–316. 2016. View Article : Google Scholar :
|
|
17
|
Pancreatic Cancer Europe Pancreatic Cancer
Inequality Report. https://www.pancreaticcancereuropeeu/campaign/the-pancreatic-cancer-europe-inequality-report/.
2018
|
|
18
|
Klein AP, Lindström S, Mendelsohn JB,
Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger
S, Gross M, Helzlsouer K, et al: An absolute risk model to identify
individuals at elevated risk for pancreatic cancer in the general
population. PLoS One. 8:e723112013. View Article : Google Scholar :
|
|
19
|
Whitcomb DC: Genetics of alcoholic and
nonalcoholic pancreatitis. Curr Opin Gastroenterol. 28:501–506.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whitcomb DC, Gorry MC, Preston RA, Furey
W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST,
Toskes PP, et al: Hereditary pancreatitis is caused by a mutation
in the cationic trypsinogen gene. Nat Genet. 14:141–145. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Witt H, Luck W, Hennies HC, Classen M,
Kage A, Lass U, Landt O and Becker M: Mutations in the gene
encoding the serine protease inhibitor, Kazal type 1 are associated
with chronic pancreatitis. Nat Genet. 25:213–216. 2000. View Article : Google Scholar
|
|
22
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giardiello FM, Brensinger JD, Tersmette
AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M and Offerhaus
JA: Very high risk of cancer in familial Peutz-Jeghers syndrome.
Gastroenterology. 119:1447–1453. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iqbal J, Ragone A, Lubinski J, Lynch HT,
Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL,
et al: The incidence of pancreatic cancer in BRCA1 and BRCA2
mutation carriers. Br J Cancer. 107:2005–2009. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kastrinos F, Mukherjee B, Tayob N, Wang F,
Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB and
Syngal S: Risk of pancreatic cancer in families with Lynch
syndrome. JAMA. 302:1790–1795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moskaluk CA, Hruban H, Lietman A, Smyrk T,
Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT and Kern
SE: Novel germline p16(INK4) allele (Asp145Cys) in a family with
multiple pancreatic carcinomas. Mutations in brief no 148 Online.
Hum Mutat. 12:701998. View Article : Google Scholar
|
|
27
|
Vasen HF, Gruis NA, Frants RR, van Der
Velden PA, Hille ET and Bergman W: Risk of developing pancreatic
cancer in families with familial atypical multiple mole melanoma
associated with a specific 19 deletion of p16 (p16-Leiden). Int J
Cancer. 87:809–811. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goldstein AM, Struewing JP, Fraser MC,
Smith MW and Tucker MA: Prospective risk of cancer in CDKN2A
germline mutation carriers. J Med Genet. 41:421–424. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rutter JL, Bromley CM, Goldstein AM, Elder
DE, Holly EA, Guerry D IV, Hartge P, Struewing JP, Hogg D, Halpern
A, et al: Heterogeneity of risk for melanoma and pancreatic and
digestive malignancies: A melanoma case-control study. Cancer.
101:2809–2816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizrahi JD, Surana R, Valle JW and Shroff
RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iacobuzio-Donahue CA: Genetic evolution of
pancreatic cancer: Lessons learnt from the pancreatic cancer genome
sequencing project. Gut. 61:1085–1094. 2012. View Article : Google Scholar
|
|
32
|
Noë M, Rezaee N, Asrani K, Skaro M, Groot
VP, Wu PH, Olson MT, Hong SM, Kim SJ, Weiss MJ, et al:
Immunolabeling of cleared human pancreata provides insights into
three-dimensional pancreatic anatomy and pathology. Am J Pathol.
188:1530–1535. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamada M, Sugiura T, Okamura Y, Ito T,
Yamamoto Y, Ashida R, Sasaki K, Nagino M and Uesaka K: Microscopic
venous invasion in pancreatic cancer. Ann Surg Oncol. 25:1043–1051.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Costa-Silva B, Aiello NM, Ocean AJ, Singh
S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et
al: Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 17:816–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fidler IJ and Poste G: The 'seed and soil'
hypothesis revisited. Lancet Oncol. 9:8082008. View Article : Google Scholar
|
|
36
|
Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ,
Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, et al: The molecular
biology of pancreatic adenocarcinoma: Translational challenges and
clinical perspectives. Signal Transduct Target Ther. 6:2492021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Campbell PJ, Yachida S, Mudie LJ, Stephens
PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren
S, Lin ML, et al: The patterns and dynamics of genomic instability
in metastatic pancreatic cancer. Nature. 467:1109–1113. 2010.
View Article : Google Scholar
|
|
38
|
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K,
Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J,
et al: Transcription phenotypes of pancreatic cancer are driven by
genomic events during tumor evolution. Nat Genet. 52:231–240. 2020.
View Article : Google Scholar
|
|
39
|
Hruban RH, Gaida MM, Thompson E, Hong SM,
Noë M, Brosens LA, Jongepier M, Offerhaus GJA and Wood LD: Why is
pancreatic cancer so deadly? The Pathologist's view. J Pathol.
248:131–141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cancer Genome Atlas Research Network:
Electronic address: simpleandrew_aguirre@dfci.harvard.edu
and Cancer Genome Atlas Research Network: Integrated genomic
characterization of pancreatic ductal adenocarcinoma. Cancer Cell.
32:185–203.e13. 2017. View Article : Google Scholar
|
|
41
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
Pancreatic Adenocarcinoma. Version 1.2020. November 26–2019.
|
|
43
|
Lambert A, Schwarz L, Borbath I, Henry A,
Van Laethem JL, Malka D, Ducreux M and Conroy T: An update on
treatment options for pancreatic adenocarcinoma. Ther Adv Med
Oncol. 11:17588359198755682019. View Article : Google Scholar :
|
|
44
|
Devisetty K and Wong SJ: Neoadjuvant
versus induction chemotherapy: More than semantics. J Clin Oncol.
31:2971–2972. 2013. View Article : Google Scholar
|
|
45
|
NIH-National Cancer Institute NCI
Dictionary of Cancer Terms. Available from: http://www.cancergov/dictionary. Accessed September
27, 2021.
|
|
46
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
Pancreatic Adenocarcinoma Version 2.0 2021-February 25 2021.
www.nccn.org. 2021
|
|
47
|
Napolitano F, Formisano L, Giardino A,
Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R,
Mozzillo E, Carratù AC, et al: Neoadjuvant treatment in locally
advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or
gemcitabine NabPaclitaxel: A single-center experience and a
literature review. Cancers (Basel). 11:9812019. View Article : Google Scholar
|
|
48
|
Macedo FI, Ryon E, Maithel SK, Lee RM,
Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, et
al: Survival outcomes associated with clinical and pathological
response following neoadjuvant FOLFIRINOX or
gemcitabine/Nab-paclitaxel chemotherapy in resected pancreatic
cancer. Ann Surg. 270:400–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ghaneh P, Palmer DH, Cicconi S, Halloran
C, Psarelli E, Rawcliffe C, Sripadam R, Mukherjee S, Wadsley J,
Al-Mukhtar A, et al: ESPAC-5F: Four-arm, prospective, multi-center,
international randomized phase II trial of immediate surgery
compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or
FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline
resectable pancreatic cancer. J Clin Oncol. 38:4505. 2020.
View Article : Google Scholar
|
|
50
|
Truty MJ, Kendrick ML, Nagorney DM, Smoot
RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG,
Harmsen WS, et al: Factors predicting response, perioperative
outcomes, and survival following total neoadjuvant therapy for
Borderline/locally advanced pancreatic cancer. Ann Surg.
273:341–349. 2021. View Article : Google Scholar
|
|
51
|
Kaufmann B, Hartmann D, D'Haese JG,
Stupakov P, Radenkovic D, Gloor B and Friess H: Neoadjuvant
treatment for borderline resectable pancreatic ductal
adenocarcinoma. Dig Surg. 36:455–461. 2019. View Article : Google Scholar
|
|
52
|
Hammel P, Huguet F, van Laethem JL,
Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J,
André T, et al: Effect of chemoradiotherapy vs chemotherapy on
survival in patients with locally advanced pancreatic cancer
controlled after 4 months of gemcitabine with or without erlotinib:
The LAP07 randomized clinical trial. JAMA. 315:1844–1853. 2016.
View Article : Google Scholar
|
|
53
|
Hammel P, Lacy J, Portales F, Sobrero AF,
Pazo Cid RA, Mozo JLM, Terrebonne E, Dowden SD, Li JS, Ong TJ, et
al: Phase II LAPACT trial of nab-paclitaxel (nab-P) plus
gemcitabine (G) for patients with locally advanced pancreatic
cancer (LAPC). J Clin Oncol. 36:2042018. View Article : Google Scholar
|
|
54
|
Hurt CN, Falk S, Crosby T, McDonald A, Ray
R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T and
Mukherjee S: Long-term results and recurrence patterns from SCALOP:
A phase II randomised trial of gemcitabine- or capecitabine-based
chemoradiation for locally advanced pancreatic cancer. Br J Cancer.
116:1264–1270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mukherjee S, Hurt CN, Bridgewater J, Falk
S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G,
et al: Gemcitabine-based or capecitabine-based chemoradiotherapy
for locally advanced pancreatic cancer (SCALOP): A multicentre,
randomised, phase 2 trial. Lancet Oncol. 14:317–326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pietrasz D, Turrini O, Vendrely V, Simon
JM, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N,
et al: How does chemoradiotherapy following induction FOLFIRINOX
improve the results in resected borderline or locally advanced
pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort. Ann
Surg Oncol. 26:109–117. 2019. View Article : Google Scholar
|
|
57
|
Katz MH, Ou FS, Herman JM, Ahmad SA,
Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, et al:
Alliance for clinical trials in oncology (ALLIANCE) trial A021501:
Preoperative extended chemotherapy vs. chemotherapy plus
hypofractionated radiation therapy for borderline resectable
adenocarcinoma of the head of the pancreas. BMC Cancer. 17:5052017.
View Article : Google Scholar :
|
|
58
|
Zhong J, Patel K, Switchenko J, Cassidy
RJ, Hall WA, Gillespie T, Patel PR, Kooby D and Landry J: Outcomes
for patients with locally advanced pancreatic adenocarcinoma
treated with stereotactic body radiation therapy versus
conventionally fractionated radiation. Cancer. 123:3486–3493. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sohal DP, Kennedy EB, Khorana A, Copur MS,
Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly
EM, Philip PA, et al: Metastatic pancreatic cancer: ASCO clinical
practice guideline update. J Clin Oncol. 36:2545–2556. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sultana A, Tudur Smith C, Cunningham D,
Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of
chemotherapy for locally advanced and metastatic pancreatic cancer:
Results of secondary end points analyses. Br J Cancer. 99:6–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ciliberto D, Botta C, Correale P, Rossi M,
Caraglia M, Tassone P and Tagliaferri P: Role of gemcitabine-based
combination therapy in the management of advanced pancreatic
cancer: A meta-analysis of randomised trials. Eur J Cancer.
49:593–603. 2013. View Article : Google Scholar
|
|
65
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar
|
|
66
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar
|
|
67
|
Pusceddu S, Ghidini M, Torchio M, Corti F,
Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo
M, et al: Comparative effectiveness of gemcitabine plus
nab-Paclitaxel and FOLFIRINOX in the First-Line setting of
metastatic pancreatic cancer: A systematic review and
Meta-Analysis. cancers (Basel). 11:4842019. View Article : Google Scholar
|
|
68
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen
L and Zhou J: Nab-paclitaxel plus S-1 versus nab-paclitaxel plus
gemcitabine as first-line chemotherapy in patients with advanced
pancreatic ductal adenocarcinoma: A randomized study. J Cancer Res
Clin Oncol. 147:1529–1536. 2021. View Article : Google Scholar
|
|
70
|
Ducreux M, Cuhna AS, Caramella C,
Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van
Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 26(Suppl 5): v56–v68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sohal DP, Mangu PB, Khorana AA, Shah MA,
Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH,
Engebretson A, et al: Metastatic pancreatic cancer: American
society of clinical oncology clinical practice guideline. J Clin
Oncol. 34:2784–2796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ghosn M, Saroufim A, Kattan J, Chahine G,
Nasr F and Farhat F: Sequential FOLFOX-6 and gemcitabine for
locally advanced and/or metastatic pancreatic cancer. Med Oncol.
29:2831–2837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Dahan L, Phelip JM, Malicot KL, Williet N,
Desrame J, Volet J, Petorin C, Malka D, Rebischung C, Aparicio T,
et al: FOLFIRINOX until progression, FOLFIRINOX with maintenance
treatment, or sequential treatment with gemcitabine and FOLFIRI.3
for first-line treatment of metastatic pancreatic cancer: A
randomized phase II trial (PRODIGE 35-PANOPTIMOX). 2018 ASCO Annual
Meeting I Gastrointestinal (noncolorectal). J Clin Oncol.
36:40002018. View Article : Google Scholar
|
|
74
|
International Society of Geriatric
Oncology Population Demographics-Cancer Epidemiology. 2021.
|
|
75
|
GBD 2017 Pancreatic Cancer Collaborators:
The global, regional, and national burden of pancreatic cancer and
its attributable risk factors in 195 countries and territories,
1990-2017: A systematic analysis for the Global Burden of Disease
Study 2017. Lancet Gastroenterol Hepatol. 4:934–947. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lamont EB, Schilsky RL, He Y, Muss H,
Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R,
et al: Generalizability of trial results to elderly Medicare
patients with advanced solid tumors (Alliance 70802). J Natl Cancer
Inst. 107:3362015. View Article : Google Scholar
|
|
77
|
Higuera O, Ghanem I, Nasimi R, Prieto I,
Koren L and Feliu J: Management of pancreatic cancer in the
elderly. World J Gastroenterol. 22:764–775. 2016. View Article : Google Scholar :
|
|
78
|
Petrillo A, Pappalardo A, Calabrese F,
Tirino G, Pompella L, Ventriglia J, Laterza MM, Caterino M, Sforza
V, Iranzo V, et al: First line nab-paclitaxel plus gemcitabine in
elderly metastatic pancreatic patients: A good choice beyond age. J
Gastrointest Oncol. 10:910–917. 2019. View Article : Google Scholar :
|
|
79
|
Martin JL, Sidhu S, Benhayoun N, Dedonno M
and Brenner WS: Dosing modifications to increase tolerability of
gemcitabine and nab-paclitaxel in treatment of pancreatic cancer in
the elderly. J Clin Oncol. 37:4412019. View Article : Google Scholar
|
|
80
|
Li D, Capanu M, Yu KH, Lowery MA, Kelsen
DP and O'Reilly EM: Treatment, outcomes, and clinical trial
participation in elderly patients with metastatic pancreas
adenocarcinoma. Clin Colorectal Cancer. 14:269–276.e1. 2015.
View Article : Google Scholar
|
|
81
|
Guion-Dusserre JF, Bertaut A, Ghiringhelli
F, Vincent J, Quipourt V, Marilier S, Tharin Z and Bengrine-Lefevre
L: Folfirinox in elderly patients with pancreatic or colorectal
cancer-tolerance and efficacy. World J Gastroenterol. 22:9378–9386.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yamamoto T, Sunakawa Y, Kubota Y, Tagawa
T, Kaga Y, Uto TIY, Kitahara Y, Toshima H, Kobayashi K, Kitahara A,
et al: Tolerability and clinical outcomes in elderly patients with
advanced pancreatic cancer treated with FOLFIRINOX. J Clin Oncol.
34:4042016. View Article : Google Scholar
|
|
83
|
Alessandretti MB, Moreira RB, Brandao EP,
Gomes JR and Amarante PM: Safety and efficacy of modified
dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years
with advanced pancreatic adenocarcinoma. J Clin Oncol. 33:4682015.
View Article : Google Scholar
|
|
84
|
Michalaki V, Poydorou A, Vezakis A,
Frangulidis G, Theodosopoulos T and Papadimitriou C: Gemcitabine
plus capecitabine in elderly patients with advanced pancreatic
cancer. Ann Oncol. 28:iii762017. View Article : Google Scholar
|
|
85
|
Marsanic P, Mellano A, Sottile A and De
Simone M: Irreversible electroporation as treatment of locally
advanced and as margin accentuation in borderline resectable
pancreatic adenocarcinoma. Med Biol Eng Comput. 55:1123–1127. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Sohal DP, Kennedy EB, Cinar P, Conroy T,
Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T,
Krishnamurthi S, et al: Metastatic pancreatic cancer: ASCO
guideline update. J Clin Oncol. Aug 5–2020.Epub ahead of print.
View Article : Google Scholar
|
|
87
|
Macarulla T, Pazo-Cid R, Guillén-Ponce C,
López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz
Beveridge R, La Casta A, et al: Phase I/II Trial to evaluate the
efficacy and safety of nanoparticle albumin-bound paclitaxel in
combination with gemcitabine in patients with pancreatic cancer and
an ECOG performance status of 2. J Clin Oncol. 37:230–238. 2019.
View Article : Google Scholar
|
|
88
|
Cunningham D, Chau I, Stocken DD, Valle
JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J,
et al: Phase III randomized comparison of gemcitabine versus
gemcitabine plus capecitabine in patients with advanced pancreatic
cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Smith AL, Wong C, Cuggia A, Borgida A,
Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, et
al: Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM
mutations in pancreatic cancer: Mutation prevalence and clinical
outcomes from two canadian research registries. JCO Precision
Oncology. Jan 19–2018. View Article : Google Scholar
|
|
90
|
Gudmundsdottir K and Ashworth A: The roles
of BRCA1 and BRCA2 and associated proteins in the maintenance of
genomic stability. Oncogene. 25:5864–5874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rebelatto TF, Falavigna M, Pozzari M,
Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S and Fazio N:
Should platinum-based chemotherapy be preferred for germline BReast
CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal
adenocarcinoma (PDAC) patients? A systematic review and
meta-analysis. Cancer Treat Rev. 80:1018952019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Stoffel EM, McKernin SE, Brand R, Canto M,
Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM,
Yurgelun M and Khorana AA: Evaluating susceptibility to pancreatic
cancer: ASCO provisional clinical opinion. J Clin Oncol.
37:153–164. 2019. View Article : Google Scholar
|
|
93
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
Pancreatic Adenocarcinoma. Version 1.2021. October. 23–2020.
|
|
94
|
Golan T, Hammel P, Reni M, Van Cutsem E,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance olaparib for germline BRCA-mutated metastatic
pancreatic cancer. N Engl J Med. 381:317–327. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Hammel P, Kindler HL, Reni M, Van Cutsem
E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Health-related quality of life in patients with a germline BRCA
mutation and metastatic pancreatic cancer receiving maintenance
olaparib. Ann Oncol. 30:1959–1968. 2019. View Article : Google Scholar
|
|
96
|
Golan T, Hammel P, Reni M, et al: Final
overall survival results from the phase 3 POLO trial: Maintenance
olaparib for germline BRCA-mutated metastatic pancreatic cancer.
In: 2021 Gastrointestinal Cancer Symposium. Oral Presentation GI21
presented at ASCO-GI, 2021;
|
|
97
|
O'Reilly EM, Lee JW, Zalupski M, Capanu M,
Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, et al:
Randomized, multicenter, phase ii trial of gemcitabine and
cisplatin with or without veliparib in patients with pancreas
adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol.
38:1378–1388. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wattenberg MM, Asch D, Yu S, O'Dwyer PJ,
Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES and
Reiss KA: Platinum response characteristics of patients with
pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or
PALB2 mutation. Br J Cancer. 122:333–339. 2020. View Article : Google Scholar :
|
|
99
|
Nishikawa G, Booth C and Prasad V:
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial
change clinical practice? Cancer. 126:4087–4088. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Rahma OE, Duffy A, Liewehr DJ, Steinberg
SM and Greten TF: Second-line treatment in advanced pancreatic
cancer: A comprehensive analysis of published clinical trials. Ann
Oncol. 24:1972–1979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Lee K, Bang K, Yoo C, Hwang I, Jeong JH,
Chang HM, Oh D, Song TJ, Park DH, Lee SS, et al: Clinical outcomes
of second-line chemotherapy after progression on Nab-paclitaxel
plus gemcitabine in patients with metastatic pancreatic
adenocarcinoma. Cancer Res Treat. 52:254–262. 2020. View Article : Google Scholar :
|
|
102
|
Sonbol MB, Firwana B, Wang Z,
Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH and
Bekaii-Saab T: Second-line treatment in patients with pancreatic
ductal adenocarcinoma: A meta-analysis. Cancer. 123:4680–4686.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Cherri S, Noventa S and Zaniboni A:
Pancreatic adenocarcinoma: Beyond first line, where are we? World J
Gastroenterol. 27:1847–1863. 2021. View Article : Google Scholar :
|
|
104
|
Oettle H, Riess H, Stieler JM, Heil G,
Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, et
al: Second-line oxaliplatin, folinic acid, and fluorouracil versus
folinic acid and fluorouracil alone for gemcitabine-refractory
pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol.
32:2423–2429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gill S, Ko YJ, Cripps C, Beaudoin A,
Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, et
al: PANCREOX: A randomized phase III study of
Fluorouracil/Leucovorin with or without oxaliplatin for second-line
advanced pancreatic cancer in patients who have received
gemcitabine-based chemotherapy. J Clin Oncol. 34:3914–3920. 2016.
View Article : Google Scholar
|
|
106
|
Xiong HQ, Varadhachary GR, Blais JC, Hess
KR, Abbruzzese JL and Wolff RA: Phase 2 trial of oxaliplatin plus
capecitabine (XELOX) as second-line therapy for patients with
advanced pancreatic cancer. Cancer. 113:2046–2052. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ohkawa S, Okusaka T, Isayama H, Fukutomi
A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y,
Nakamori S, et al: Randomised phase II trial of S-1 plus
oxaliplatin vs S-1 in patients with gemcitabine-refractory
pancreatic cancer. Br J Cancer. 112:1428–1434. 2015. View Article : Google Scholar :
|
|
108
|
Fortune BE, Li X, Kosuri KV, Weatherby LM,
Thomas JP and Bekaii-Saab TS: Fixed-dose-rate gemcitabine in
combination with oxaliplatin in patients with metastatic pancreatic
cancer refractory to standard-dose-rate gemcitabine: A
single-institute study. Oncology. 76:333–337. 2009. View Article : Google Scholar
|
|
109
|
Demols A, Peeters M, Polus M, Marechal R,
Gay F, Monsaert E, Hendlisz A and Van Laethem JL: Gemcitabine and
oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic
adenocarcinoma: A phase II study. Br J Cancer. 94:481–485. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ramfidis VS, Syrigos KN and Saif MW: New
therapeutic strategies in the second line setting of advanced or
metastatic pancreatic adenocarcinoma. JOP. 14:344–346.
2013.PubMed/NCBI
|
|
111
|
Portal A, Pernot S, Tougeron D, Arbaud C,
Bidault AT, de la Fouchardière C, Hammel P, Lecomte T, Dréanic J,
Coriat R, et al: Nab-paclitaxel plus gemcitabine for metastatic
pancreatic adenocarcinoma after Folfirinox failure: An AGEO
prospective multicentre cohort. Br J Cancer. 113:989–995. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite Instability/Mismatch
Repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar
|
|
115
|
Bockorny B, Semenisty V, Macarulla T,
Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ,
Pedersen KS, et al: BL-8040, a CXCR4 antagonist, in combination
with pembrolizumab and chemotherapy for pancreatic cancer: The
COMBAT trial. Nat Med. 26:878–885. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Okamura R, Boichard A, Kato S, Sicklick
JK, Bazhenova L and Kurzrock R: Analysis of NTRK alterations in
pan-cancer adult and pediatric malignancies: Implications for
NTRK-Targeted therapeutics. JCO Precis Oncol 2018. PO18.00183.
2018. View Article : Google Scholar
|
|
117
|
Solomon JP, Linkov I, Rosado A, Mullaney
K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A,
et al: NTRK fusion detection across multiple assays and 33,997
cases: Diagnostic implications and pitfalls. Mod Pathol. 33:38–46.
2020. View Article : Google Scholar :
|
|
118
|
O'Reilly EM and Hechtman JF: Tumour
response to TRK inhibition in a patient with pancreatic
adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 30(Suppl
8): viii36–viii40. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Doebele RC, Drilon A, Paz-Ares L, Siena S,
Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al:
Entrectinib in patients with advanced or metastatic NTRK
fusion-positive solid tumours: Integrated analysis of three phase
1-2 trials. Lancet Oncol. 21:271–282. 2020. View Article : Google Scholar
|
|
120
|
Wang-Gillam A, Hubner RA, Siveke JT, Von
Hoff DD, Belanger B, de Jong FA, Mirakhur B and Chen LT: NAPOLI-1
phase 3 study of liposomal irinotecan in metastatic pancreatic
cancer: Final overall survival analysis and characteristics of
long-term survivors. Eur J Cancer. 108:78–87. 2019. View Article : Google Scholar
|
|
121
|
Humphris JL, Patch AM, Nones K, Bailey PJ,
Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, et al:
Hypermutation in pancreatic cancer. Gastroenterology. 152:68–74.e2.
2017. View Article : Google Scholar
|
|
122
|
Leem G and Song SY: Immunotherapy in
pancreatic cancer; the road less traveled. Immunol Disord
Immunother. 1:1062016. View Article : Google Scholar
|
|
123
|
Hayashi A, Hong J and Iacobuzio-Donahue
CA: The pancreatic cancer genome revisited. Nat Rev Gastroenterol
Hepatol. 18:469–481. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Nedaeinia R, Avan A, Manian M, Salehi R
and Ghayour-Mobarhan M: EGFR as a potential target for the
treatment of pancreatic cancer: Dilemma and controversies. Curr
Drug Targets. 15:1293–1301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Navas C, Hernández-Porras I, Schuhmacher
AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is
essential for k-ras oncogene-driven pancreatic ductal
adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Matsuoka T and Yashiro M: Molecular
targets for the treatment of pancreatic cancer: Clinical and
experimental studies. World J Gastroenterol. 22:776–789. 2016.
View Article : Google Scholar :
|
|
127
|
Nywening TM, Wang-Gillam A, Sanford DE,
Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA,
Yano M, et al: Targeting tumour-associated macrophages with CCR2
inhibition in combination with FOLFIRINOX in patients with
borderline resectable and locally advanced pancreatic cancer: A
single-centre, open-label, dose-finding, non-randomised, phase 1b
trial. Lancet Oncol. 17:651–662. 2016. View Article : Google Scholar
|
|
128
|
Kamerkar S, LeBleu VS, Sugimoto H, Yang S,
Ruivo CF, Melo SA, Lee JJ and Kalluri R: Exosomes facilitate
therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Nature. 546:498–503. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
ClinicalTrials.gov: National Library of
Medicine (US): 2000 Feb 29. Identifier NCT03608631, iExosomes in
Treating Participants with Metastatic Pancreas Cancer with KrasG12D
Mutation. August 1, 2018 [cited 2020 June 29]. Bethesda, MD, 2020.
Available from: https://clinicaltrials.gov/ct2/show/NCT03608631.
|
|
130
|
Garrido-Laguna I, Uson M, Rajeshkumar NV,
Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor
G, Sharma R, et al: Tumor engraftment in nude mice and enrichment
in stroma-related gene pathways predict poor survival and
resistance to gemcitabine in patients with pancreatic cancer. Clin
Cancer Res. 17:5793–5800. 2011. View Article : Google Scholar :
|
|
131
|
Yachida S and Iacobuzio-Donahue CA: The
pathology and genetics of metastatic pancreatic cancer. Arch Pathol
Lab Med. 133:413–422. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Provenzano PP, Cuevas C, Chang AE, Goel
VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma
ablates physical barriers to treatment of pancreatic ductal
adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sherman MH, Yu RT, Engle DD, Ding N,
Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S,
et al: Vitamin D receptor-mediated stromal reprogramming suppresses
pancreatitis and enhances pancreatic cancer therapy. Cell.
159:80–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
van Duijnhoven FJB, Jenab M, Hveem K,
Siersema PD, Fedirko V, Duell EJ, Kampman E, Halfweeg A, van Kranen
HJ, van den Ouweland JM, et al: Circulating concentrations of
vitamin D in relation to pancreatic cancer risk in European
populations. Int J Cancer. 142:1189–1201. 2018. View Article : Google Scholar :
|
|
136
|
Gorchs L, Ahmed S, Mayer C, Knauf A,
Fernández Moro C, Svensson M, Heuchel R, Rangelova E, Bergman P and
Kaipe H: The vitamin D analogue calcipotriol promotes an
anti-tumorigenic phenotype of human pancreatic CAFs but reduces T
cell mediated immunity. Sci Rep. 10:174442020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Le Large TY, Bijlsma MF, Kazemier G, van
Laarhoven HW, Giovannetti E and Jimenez CR: Key biological
processes driving metastatic spread of pancreatic cancer as
identified by multi-omics studies. Semin Cancer Biol. 44:153–169.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Sano M, Ijichi H, Takahashi R, Miyabayashi
K, Fujiwara H, Yamada T, Kato H, Nakatsuka T, Tanaka Y, Tateishi K,
et al: Blocking CXCLs-CXCR2 axis in tumor-stromal interactions
contributes to survival in a mouse model of pancreatic ductal
adenocarcinoma through reduced cell invasion/migration and a shift
of immune-inflammatory microenvironment. Oncogenesis. 8:82019.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Pishvaian MJ, Rolfo CD, Liu SV, Multani
PS, Maneval EC and Garrido-Laguna I: Clinical benefit of
entrectinib for patients with metastatic pancreatic cancer who
harbor NTRK and ROS1 fusions. J Clin Oncol. 36:5212018. View Article : Google Scholar
|
|
140
|
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ,
Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, et al: Safety and
antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK
inhibitor entrectinib: Combined results from two phase I trials
(ALKA-372-001 and STARTRK-1). Cancer Discov. 7:400–409. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Yan HH, Jung KH, Son MK, Fang Z, Kim SJ,
Ryu YL, Kim J, Kim MH and Hong SS: Crizotinib exhibits antitumor
activity by targeting ALK signaling not c-MET in pancreatic cancer.
Oncotarget. 5:9150–9168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Herreros-Villanueva M and Bujanda L:
Non-invasive biomarkers in pancreatic cancer diagnosis: What we
need versus what we have. Ann Transl Med. 4:1342016. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Humphris JL, Chang DK, Johns AL, Scarlett
CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA,
et al: The prognostic and predictive value of serum CA19.9 in
pancreatic cancer. Ann Oncol. 23:1713–1722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Zhang Y, Yang J, Li H, Wu Y, Zhang H and
Chen W: Tumor markers CA19-9 CA242 and CEA in the diagnosis of
pancreatic cancer: A meta-analysis. Int J Clin Exp Med.
8:11683–11691. 2015.
|
|
145
|
Kaur S, Baine MJ, Jain M, Sasson AR and
Batra SK: Early diagnosis of pancreatic cancer: Challenges and new
developments. Biomark Med. 6:597–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Locker GY, Hamilton S, Harris J, Jessup
JM, Kemeny N, Macdonald JS, Somerfield MR and Hayes DF: ASCO 2006
update of recommendations for the use of tumor markers in
gastrointestinal cancer. J Clin Oncol. 24:5313–5327. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Goonetilleke KS and Siriwardena AK:
Systematic review of carbohydrate antigen (CA 19-9) as a
biochemical marker in the diagnosis of pancreatic cancer. Eur J
Surg Oncol. 33:266–270. 2007. View Article : Google Scholar
|
|
148
|
Ruivo CF, Adem B, Silva M and Melo SA: The
biology of cancer exosomes: Insights and new perspectives. Cancer
Res. 77:6480–6488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Melo SA, Luecke LB, Kahlert C, Fernandez
AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari
N, et al: Glypican-1 identifies cancer exosomes and detects early
pancreatic cancer. Nature. 523:177–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Hu W, Liu C, Bi ZY, Zhou Q, Zhang H, Li
LL, Zhang J, Zhu W, Song YY and Zhang F: Comprehensive landscape of
extracellular vesicle-derived RNAs in cancer initiation,
progression, metastasis and cancer immunology. Mol Cancer.
19:1022020. View Article : Google Scholar : PubMed/NCBI
|
